Inmode Ltd

InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

InMode reports record revenue, plans global expansion for growth

InMode's strong financial performance in Q4 and full year 2022, driven by successful product launches and global expansion efforts, positions the company for continued growth. Despite challenges in pinpointing market penetration, opportunities lie in new product launches and untapped physician markets.

InMode reports robust Q1 earnings, eyes international expansion and talent

InMode delivered strong Q1 2023 results, driven by revenue growth, international expansion, and strategic hiring practices, positioning the company for continued success.
While facing challenges such as rising operating expenses and talent acquisition complexities, InMode's focus on quality, innovation, and financial strength presents opportunities for sustainable growth.
By leveraging opportunities in talent acquisition, product innovation, and international expansion, InMode can enhance market competitiveness and drive long-term value creation.
Overall, InMode's performance, strengths, and strategic outlook indicate a positive trajectory for future growth and profitability, supported by a solid financial foundation.

InMode achieves record Q2 earnings, eyes global expansion and innovation

InMode's strong financial performance, global expansion, and focus on innovation position it well for future growth. While facing challenges in managing increased expenses and scaling sales, the company's strategic investments and market positioning offer promising opportunities for expansion and market leadership.

InMode reports steady Q3 growth amidst challenges and opportunities

InMode's Q3 performance reflects resilience amid industry seasonality and macro challenges, with revenue growth and strong margins.
The company's focus on innovation, IP protection, and strategic acquisitions positions it for sustained leadership and growth.
Challenges in leasing processes and legal battles require proactive management, but opportunities in M&A and product growth remain.
Despite uncertainties for 2024, InMode's strategic initiatives and market presence offer a foundation for future success.

InMode reports record 2023 revenue, eyes international expansion and M&A

InMode navigated industry challenges in 2023 with resilience, focusing on innovation, global expansion, and cost management. Despite facing headwinds, the company remains optimistic about growth opportunities, leveraging its strong financial position and strategic initiatives for future success.

InMode reports Q1 revenue of $80.3M, adjusts guidance for 2024

InMode faces challenges from industry headwinds and manufacturing delays but shows strength in new platform launches and North America performance.
Opportunities lie in strategic initiatives, market demand confidence, and growth potential from new platforms.
Guidance adjustments reflect proactive measures to navigate uncertainties and drive future growth.
Overall, InMode remains resilient amidst challenges, poised for growth with strategic focus areas.

InMode reports Q2 revenue of $86.4 million, adjusts 2024 guidance

InMode faces challenges with declining demand for treatments and international sales, but is leveraging new platform launches and cost management to drive performance. The company is adapting to market conditions and geopolitical issues to capitalize on growth opportunities.

InMode reports Q3 revenue of $130.2M, revises guidance amid challenges

InMode faced challenges from macroeconomic headwinds, impacting international sales and necessitating a revision of full-year guidance.
Despite these challenges, the company demonstrated strong operational performance with high gross margins and strategic management changes.
Opportunities lie in new platform adoption, market realignment, and leveraging the strong cash position for future growth.
Overall, InMode remains well-positioned to navigate challenges and capitalize on opportunities for sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teladoc

Teladoc is trading at its cheapest ever in relation to sales -- and future prospects look bright. InMode recently reported record revenue and earnings.

Got $100? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond

InMode has a strong competitive position in the rapidly growing global aesthetic market with its innovative products and technology. The company has achieved impressive financial performance with significant revenue growth, strong margins, and no debt.

InMode: Potential To Double Amid Strong Growth Prospects And Favorable Market Position

YOKNEAM, Israel, March 13, 2023 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that that it does not hold cash deposits or securities at Silicon Valley Bank.

InMode Updates It Does Not Hold Cash Deposits at SVB

With a 44% margin of safety, InMode Ltd. is a growth company trading at value prices. InMode's full-year 2022 results and earnings call did little to quell investor frustrations and concerns over future growth.

InMode: Key Takeaways From 2022 Full-Year Results

Amazon

Growth stocks have been beaten down, but Wall Street analysts expect some stocks to soar in the near term. The average investment bank analyst who follows Amazon thinks it can rise more than 40% in the year ahead.

2 Exceptional Growth Stocks That Could Jump 37.6% to 40.2% Higher, According to Wall Street

YOKNEAM, Israel, March 2, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer, will present in-person at the Barclays Global Health Conference in Miami on March 15, 2023.

InMode to Present In-Person at the Barclays Global Health Conference

Maravai LifeSciences Holdings

There isn't much that's stopping them from penetrating their markets globally.

Don't Miss Out on These 2 Undervalued Stocks With Huge Growth Potential

23andMe

Both are likely to double quite soon, and they aren't even that risky.

2 High-Growth Stocks That Could Double Your Money in 5 Years or Less

Bionano Genomics

Both have growth catalysts on the way, and plenty of recurring revenue too.

Get Ready to Soar: 2 High-Octane Growth Stocks Wall Street Expects to Climb in 2023

Snowflake

SoFi Technologies

Investing in under-the-radar growth stocks can be a great way to gain exposure to companies that have the potential to outperform the market. By investing in these stocks, investors can capitalize on opportunities that may not be apparent to the wider public.

3 Under-the-Radar Growth Stocks with Promising Fundamentals

Doximity

You don't have to be rich to get your money to start working for you.

2 Terrific Growth Stocks to Buy With $200 Right Now

Outset Medical

Here are the "ins and outs" for these two stocks.

Better Medtech Stock to Buy: InMode or Outset Medical?

InMode Ltd. (NASDAQ:INMD ) Q4 2022 Results Conference Call February 14, 2023 8:30 AM ET Company Participants Miri Segal - Investor Relations, MS-IR LLC Moshe Mizrahy - Chairman and Chief Executive Officer Dr. Michael Kreindel - Co-Founder and Chief Technology Officer Yair Malca - Chief Financial Officer Shakil Lakhani - President, North America Dr. Spero Theodorou - Chief Medical Officer Rafael Lickerman - VP of Finance Conference Call Participants Matt Miksic - Barclays Jon Lee - Jefferies Kyle Rose - Canaccord Genuity Mike Matson - Needham & Company Jeff Johnson - Baird Operator Good morning, and welcome to InMode Fourth Quarter and Full Year Financial Results Conference Call.

InMode Ltd. (INMD) Q4 2022 Earnings Call Transcript

Medical aesthetics company InMode issued lighter-than-expected earnings guidance for 2023, sending INMD stock into the red early Tuesday. The post InMode Slumps On Light Earnings Outlook Despite Quarterly Beat appeared first on Investor's Business Daily.

InMode Slumps On Light Earnings Outlook Despite Quarterly Beat

YOKNEAM, Israel, Feb. 14, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year ended December 31, 2022.

InMode Reports Fourth Quarter and Full Year 2022 Financial Results; Record Quarterly Revenue of $133.6M Represents 21% Year-Over-Year Growth

Inari Medical

Find out why the investment bankers who follow these stocks think they can soar in the near term.

3 Magnificent Growth Stocks With 38% to 64% Upside Potential, According to Wall Street

InMode Ltd. is filling a treatment gap in the market with innovative, minimally invasive cosmetic procedure technologies. Most of InMode's revenue comes from growing adoption of devices. Soon, though, sales will be primarily to update its installed unit base as growth steadies.

InMode: Steady State Revenue In Sight

CRISPR Therapeutics

Moderna

These stocks all fell by double digits last year.

3 No-Brainer Growth Stocks to Buy in 2023

Although INMD's return on equity has decreased over the years, it still remains very attractive relative to most of the firms in the health care equipment industry. While the profit margin has contracted somewhat in 2022, due to the challenging macroeconomic environment, it has expanded substantially over the past years.

InMode: A Brief Analysis Of Profitability And Efficiency Reaffirms Buy Rating

InMode Ltd. has 80%+ gross margins and 40%+ operating margins within a growing industry. The market is overestimating short-term worries that likely won't have a material effect on long-term cash flows.

InMode: High Growth, High Margin Medical Device Company On Sale

InMode  Ltd ( NASDAQ:INMD) has added 35.6% over the last nine months, but more recently has consolidated below the $39 area.

Medtech Stock Could Conquer Long-Term Resistance

Analysts' price targets for this stock suggest it could soon put up some big gains.

3 Reasons Wall Street Thinks InMode Can Rocket 47% Higher in 2023

Axsome Therapeutics

2 Promising New Growth Stocks to Watch in 2023

Shockwave Medical

These stocks are all down by at least 42% from their all-time highs despite impressive performances from their underlying businesses.

3 Beaten-Down Growth Stocks That I'm Loading Up On in 2023

There are two sides of the coin with this healthcare stock.

News for Inmode Ltd Stock (INMD)